The short version of melanocortin system fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-20. Anything still debated is marked as such rather than presented as settled.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
== Mechanism == Obstructive sleep apnea The causes of obstructive sleep apnea are complex and individualized, but typical risk factors include narrow pharyngeal anatomy and craniofacial structure. When anatomical risk factors are combined with non-anatomical contributors such as an ineffective pharyngeal dilator muscle function during sleep, unstable control of breathing (high loop gain), and premature awakening to mild airway narrowing, the severity of the OSA rapidly increases as more factors are present. When breathing is paused due to upper airway obstruction, carbon dioxide builds up in the bloodstream. Chemoreceptors in the bloodstream note the high carbon dioxide levels. The brain is signaled to awaken the person, which clears the airway and allows breathing to resume. Breathing normally will restore oxygen levels and the person will fall asleep again. This carbon dioxide build-up may be due to the decrease of output of the brainstem regulating the chest wall or pharyngeal muscles, which causes the pharynx to collapse. As a result, people with sleep apnea experience reduced or no slow-wave sleep and spend less time in REM sleep. Central sleep apnea There are two main mechanism that drive the disease process of CSA, sleep-related hypoventilation and post-hyperventilation hypocapnia. The most common cause of CSA is post-hyperventilation hypocapnia secondary to heart failure. This occurs because of brief failures of the ventilatory control system but normal alveolar ventilation.
== Bibliography == Balaban, Naomi (2008). The Handy Anatomy Answer Book. Visible Ink Press. ISBN 978-1-57859-190-9. Barnes, Edward E.; Fox, Richard S.; Barnes, Robert D. (2003). Invertebrate zoology : a functional evolutionary approach (7. ed.). Belmont, Calif. [u.a.]: Thomson, Brooks/Cole. ISBN 0-03-025982-7. Forbes, R. M.; Mitchell, H. H.; Cooper, A. R. (1956). "Further studies on the gross composition and mineral elements of the adult human body". Journal of Biological Chemistry. 223 (2). American Society for Biochemistry and Molecular Biology: 969–975. doi:10.1016/S0021-9258(18)65095-1. PMID 13385244. Mish, Frederick C., ed. (2003). Merriam-Webster's Collegiate Dictionary (11th ed.). Merriam-Webster. ISBN 978-0-87779-807-1. Nasoori, Alireza (2020). "Formation, structure, and function of extra-skeletal bones in mammals". Biological Reviews. 95 (4). Cambridge Philosophical Society: 986–1019. doi:10.1111/brv.12597. PMID 32338826. S2CID 216556342. Pechenik, Jan A. (2015). Biology of the Invertebrates (7th ed.). McGraw-Hill Education. ISBN 978-0-07-352418-4. Reynolds, William W.; Karlotski, William J. (1977). "The Allometric Relationship of Skeleton Weight to Body Weight in Teleost Fishes: A Preliminary Comparison with Birds and Mammals". Copeia. 1977 (1). American Society of Ichthyologists and Herpetologists: 160–163. doi:10.2307/1443520. JSTOR 1443520. Ruppert, Edward E.; Fox, Richard S.; Barnes, Robert D. (2003). Invertebrate Zoology (7th ed.). Thomson, Brooks/Cole. ISBN 978-0-03-025982-1. Stein, Lisa (2007). Body: The Complete Human. National Geographic Society.
Stainless steel remains a piping material of choice for the pharmaceutical industry. Due to its metallic contribution, most steel was removed from microelectronics UPW systems in the 1980s and replaced with high performance polymers of polyvinylidene fluoride (PVDF), perfluoroalkoxy (PFA), ethylene chlorotrifluoroethylene (ECTFE) and polytetrafluoroethylene (PTFE) in the US and Europe. In Asia, polyvinyl chloride (PVC), chlorinated polyvinyl chloride (CPVC) and polypropylene (PP) are popular, along with the high performance polymers.
Sources: en.wikipedia.org
As he expected, withdrawal of the drug led to an increase in seizure frequency – it was not a cure. The drug was quickly adopted as the first widely effective anticonvulsant, though World War I delayed its introduction in the U.S. In 1939, a German family asked Adolf Hitler to have their disabled son killed; the five-month-old boy was given a lethal dose of Luminal after Hitler sent his own doctor to examine him. A few days later 15 psychiatrists were summoned to Hitler's Chancellery and directed to commence a clandestine program of involuntary euthanasia. In 1940, at a clinic in Ansbach, Germany, around 50 intellectually disabled children were injected with Luminal and killed that way. A plaque was erected in their memory in 1988 in the local hospital at Feuchtwanger Strasse 38, although a newer plaque does not mention that patients were killed using barbiturates on site. Luminal was used in the Nazi children's euthanasia program until at least 1943. Phenobarbital was used to treat neonatal jaundice by increasing liver metabolism and thus lowering bilirubin levels. In the 1950s, phototherapy was discovered, and became the standard treatment. Phenobarbital was used for over 25 years as prophylaxis in the treatment of febrile seizures. Although an effective treatment in preventing recurrent febrile seizures, it had no positive effect on patient outcome or risk of developing epilepsy. The treatment of simple febrile seizures with anticonvulsant prophylaxis is no longer recommended.
His Pan-Slavic views were unleashed in this book, where he stated that the land of Slovaks should be annexed by the Tsar's empire and that eventually, the population could be not only Russified, but also converted into the rite of Orthodoxy, religion originally spread by Cyril and Methodius during the times of Great Moravia, which served as an opposition to the Catholic missionaries from the Franks. After the Hungarian invasion of Pannonia, Hungarians converted into Catholicism, which effectively influenced the Slavs living in Pannonia and in the land south of the Lechs. However, the Russian Empire often claimed Pan-Slavism as a justification for its aggressive moves in the Balkan Peninsula of Europe against the Ottoman Empire, which conquered and held the land of Slavs for centuries. This eventually led to the Balkan campaign of the Russian Empire, which resulted in the entire Balkan being liberated from the Ottoman Empire, with the help and the initiative of the Russian Empire. Pan-Slavism has some supporters among Czech and Slovak politicians, especially among the nationalistic and far-right ones, such as People's Party – Our Slovakia. The creation of an independent Czechoslovakia made the old ideals of Pan-Slavism anachronistic. Relations with other Slavic states varied, sometimes being so tense it escalated into an armed conflict, such as with the Second Polish Republic where border clashes over Silesia resulted in a short hostile conflict, the Polish–Czechoslovak War. Even tensions between Czechs and Slovaks had appeared before and during World War II.
Bolognia, Jean L.; et al. (2007). Dermatology. St. Louis: Mosby. ISBN 978-1-4160-2999-1. James, William D.; et al. (2006). Andrews' Diseases of the Skin: Clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
Sources: en.wikipedia.org
=== 2024 Khabarovsk, Russia === On 5 April 2024, an emergency regime was introduced in the Russian city of Khabarovsk after a local resident accidentally discovered that radiation levels had jumped sharply in one of the industrial areas of the city. According to volunteers of the dosimetric control group, the dosimeter at the NP site showed up to 800 microsieverts, which is 1600 times the safe value. Employees of the Ministry of Emergency Situations fenced off the area to 30 by 30 meters (100 by 100 ft), where they found a capsule with caesium from a defectoscope. This was placed in a protective container and taken away for disposal. The incident was first reported by the Novaya Gazeta.
planets in the habitable zones of stars with low metallicity are the best targets to search for complex life on land." A university reports a study (29 Mar) affirming the high level of economic losses from biological invasions, showing they have risen to the level of economic damage costs from floods or earthquakes, which are also rising. 19 April A bolide is observed over Ukraine and Belarus for about five seconds. It is first observed at an altitude of 98 km above Velyka Dymerka, then passes directly above Kyiv at an altitude of 80 km and continues to the southwest with a speed of 29 km/s. A bright flare occurs at an altitude of 38 km, when the bolide's absolute magnitude reaches approximately −18. The likely cause of grey hair is shown to be pigment-making cells losing their ability to mature into melanocytes. Researchers show parrots can and enjoy to use a videocalling system. A study with mice shows that microplastics pass the blood–brain barrier (BBB), entering and accumulating in the brain, and identifies a key determinant for whether or not they pass the BBB. 20 April A new 29-year record of ice sheet mass in Greenland and Antarctica is published as part of the IMBIE collaboration. It finds that the combined ice loss in these regions has more than tripled since the early 1990s, with 2019 seeing the greatest losses of any year on record. These findings have implications for future sea level rise.
The pools of A, B, and C have delta values defined as δA, δB, and δC respectively. These values are related to the ratio of heavy to light isotopes in each pool, and are the conventional means by which scientists express the isotopic composition of materials. Importantly, δB is distinct from δb listed on the diagram, as δb is the isotopic composition of B produced from A before it mixes with the pool of B. The isotopic compositions of the pools and products are related through fractionation factors that reflect the kinetic isotope effects (KIEs) associated with each reaction. For A → B,
Plants that do not use PEP-carboxylase in carbon fixation are called C3 plants because the primary carboxylation reaction, catalyzed by RuBisCO, produces the three-carbon 3-phosphoglyceric acids directly in the Calvin-Benson cycle. Over 90% of plants use C3 carbon fixation, compared to 3% that use C4 carbon fixation; however, the evolution of C4 in over sixty plant lineages makes it a striking example of convergent evolution. C2 photosynthesis, which involves carbon-concentration by selective breakdown of photorespiratory glycine, is both an evolutionary precursor to C4 and a useful carbon-concentrating mechanism in its own right. Xerophytes, such as cacti and most succulents, also use PEP carboxylase to capture carbon dioxide in a process called Crassulacean acid metabolism (CAM). In contrast to C4 metabolism, which spatially separates the CO2 fixation to PEP from the Calvin cycle, CAM temporally separates these two processes. CAM plants have a different leaf anatomy from C3 plants, and fix the CO2 at night, when their stomata are open. CAM plants store the CO2 mostly in the form of malic acid via carboxylation of phosphoenolpyruvate to oxaloacetate, which is then reduced to malate. Decarboxylation of malate during the day releases CO2 inside the leaves, thus allowing carbon fixation to 3-phosphoglycerate by RuBisCO. CAM is used by 16,000 species of plants.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.